SAB Biotherapeutics Inc (SABS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.84-6.58%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge SAB Biotherapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	125,000
EPS	—	-0.267
Annual ending 2026-12-31
Revenue	—	333,333
EPS	—	-1.213
Annual ending 2027-12-31
Revenue	—	50,000
EPS	—	-0.801

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operations stabilizes near negative $14.27 million by 2026-Q1	A supporting condition in SAB Biotherapeutics Inc's published investment case. The stated target is >= -14.27 USD_MILLIONS.	Broken	Cash from operations worsens beyond negative $14.27 million by 2026-Q1	Cash from operations: $-24.112M FY2026-Q2; GAAP. Published target: >= -14.27 USD_MILLIONS. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-24,112,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 consecutive quarters. Operating income worsened from -$11.3M in 2024-Q3 to -$23.4M in 2026-Q2, and net income declined from -$10.3M to -$22.5M over the same period. This reflects ongoing investment in clinical development with no revenue reported. The trajectory shows increasing operating losses consistent with advancing clinical programs but no improvement in profitability yet. Delivery assessment Oct 24, 2026
Operating losses improve or stabilize near negative $20 million by 2026-Q1	If operating losses and cash burn improve, the company could stabilize.	Under Pressure	Operating losses worsen beyond negative $20 million by 2026-Q1	Operating income: $-23.377M FY2026-Q2; GAAP. Published target: >= -20.0 USD_MILLIONS. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-23,377,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c0266224-744b-4392-a8e9-18fe7758344d. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 8 consecutive quarters. Operating income worsened from -$11.3M in 2024-Q3 to -$23.4M in 2026-Q2, and net income declined from -$10.3M to -$22.5M over the same period. This reflects ongoing investment in clinical development with no revenue reported. The trajectory shows increasing operating losses consistent with advancing clinical programs but no improvement in profitability yet. Delivery assessment Oct 24, 2026
Revenue reaches at least $175 million by mid-2028	The company targets about $175 million in revenue by mid-2028.	Intact	Revenue falls below $175 million by mid-2028	Revenue: $0 FY2026-Q2; GAAP. Published target: >=175 USD_MILLIONS. Target period ends 2028-06-30; this observation covers 2026-Q2. Source published Aug 6, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2 via material event disclosure. The company formalized a manufacturing partnership with Emergent BioSolutions Canada for SAB-142 production. Financials show continued operating losses consistent with clinical-stage operations. This is an initial step toward commercial readiness but no revenue impact yet. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.80

Unavailable → $-0.80 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$62,500	4 / 8
2026-07-25	Unavailable	$62,500	4 / 8
2026-07-26	Unavailable	$62,500	4 / 8
2026-07-27	Unavailable	$62,500	4 / 8
2026-07-28	Unavailable	$62,500	4 / 8
2026-07-29	$-0.72	$50,000	5 / 5
2026-07-30	$-0.72	$50,000	5 / 5
2026-07-31	Unavailable	$62,500	4 / 8
2026-08-01	$-0.72	$50,000	5 / 5
2026-08-02	Unavailable	$62,500	4 / 8
2026-08-03	$-0.72	$50,000	5 / 5
2026-08-04	$-0.72	$50,000	5 / 5
2026-08-05	Unavailable	$62,500	4 / 8
2026-08-06	Unavailable	$62,500	4 / 8
2026-08-08	Unavailable	$62,500	4 / 8
2026-08-09	Unavailable	$62,500	4 / 8
2026-08-10	Unavailable	$62,500	4 / 8
2026-08-12	$-0.72	$50,000	5 / 5
2026-08-13	$-0.95	$71,430	5 / 7
2026-08-14	$-0.72	$50,000	5 / 5
2026-08-15	$-0.72	$50,000	5 / 5
2026-08-16	$-0.72	$50,000	6 / 5
2026-08-17	$-0.72	$50,000	6 / 5
2026-08-18	$-0.72	$50,000	6 / 5
2026-08-19	$-0.72	$50,000	6 / 5
2026-08-20	$-0.83	$50,000	6 / 5
2026-08-21	$-0.83	$50,000	6 / 5
2026-08-22	$-0.83	$50,000	6 / 5
2026-08-23	$-0.83	$50,000	6 / 5
2026-08-24	$-0.80	$50,000	6 / 5
2026-08-25	$-0.80	$50,000	6 / 5
2026-08-26	$-0.80	$50,000	6 / 5
2026-08-27	$-0.80	$50,000	6 / 5
2026-08-28	$-0.80	$50,000	6 / 5
2026-08-29	$-0.80	$50,000	6 / 5
2026-08-30	$-0.80	$50,000	6 / 5
2026-08-31	$-0.80	$50,000	6 / 5
2026-09-01	$-0.80	$50,000	6 / 5
2026-09-02	$-0.80	$50,000	6 / 5
2026-09-03	$-0.80	$50,000	6 / 5
2026-09-04	$-0.80	$50,000	6 / 5
2026-09-05	$-0.80	$50,000	6 / 5
2026-09-06	$-0.80	$50,000	6 / 5
2026-09-07	$-0.80	$50,000	6 / 5
2026-09-08	$-0.80	$50,000	6 / 5
2026-09-09	$-0.80	$50,000	6 / 5
2026-09-10	$-0.80	$50,000	6 / 5
2026-09-11	$-0.80	$50,000	6 / 5
2026-09-12	$-0.80	$50,000	6 / 5
2026-09-13	$-0.80	$50,000	6 / 5
2026-09-14	$-0.80	$50,000	6 / 5
2026-09-15	$-0.80	$50,000	6 / 5
2026-09-16	$-0.80	$50,000	6 / 5
2026-09-17	$-0.80	$50,000	6 / 5
2026-09-18	$-0.80	$50,000	6 / 5
2026-09-19	$-0.80	$50,000	6 / 5
2026-09-20	$-0.80	$50,000	6 / 5
2026-09-21	$-0.80	$50,000	6 / 5
2026-09-22	$-0.80	$50,000	6 / 5
2026-09-23	$-0.80	$50,000	6 / 5
2026-09-24	$-0.80	$50,000	6 / 5
2026-09-25	$-0.80	$50,000	6 / 5
2026-09-26	$-0.80	$50,000	6 / 5
2026-09-27	$-0.80	$50,000	6 / 5
2026-09-28	$-0.80	$50,000	6 / 5
2026-09-29	$-0.80	$50,000	6 / 5
2026-09-30	$-0.80	$50,000	6 / 5
2026-10-01	$-0.80	$50,000	6 / 5
2026-10-02	$-0.80	$50,000	6 / 5
2026-10-03	$-0.80	$50,000	6 / 5
2026-10-04	$-0.80	$50,000	6 / 5
2026-10-05	$-0.80	$50,000	6 / 5
2026-10-06	$-0.80	$50,000	6 / 5
2026-10-07	$-0.80	$50,000	6 / 5
2026-10-08	$-0.80	$50,000	6 / 5
2026-10-09	$-0.80	$50,000	6 / 5
2026-10-10	$-0.80	$50,000	6 / 5
2026-10-11	$-0.80	$50,000	6 / 5
2026-10-12	$-0.80	$50,000	6 / 5
2026-10-13	$-0.80	$50,000	6 / 5
2026-10-14	$-0.80	$50,000	6 / 5
2026-10-15	$-0.80	$50,000	6 / 5
2026-10-16	$-0.80	$50,000	6 / 5
2026-10-17	$-0.80	$50,000	6 / 5
2026-10-18	$-0.80	$50,000	6 / 5
2026-10-19	$-0.80	$50,000	6 / 5
2026-10-20	$-0.80	$50,000	6 / 5
2026-10-21	$-0.80	$50,000	6 / 5
2026-10-22	$-0.80	$50,000	6 / 5
2026-10-23	$-0.80	$50,000	6 / 5
2026-10-24	$-0.80	$50,000	6 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	0	0
2026-06-01	11	0	0
2026-07-01	11	0	0
2026-08-01	11	0	0
2026-09-01	11	0	0
2026-10-01	11	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operations stabilizes near negative $14.27 million by 2026-Q1Published status: Broken
Operating losses improve or stabilize near negative $20 million by 2026-Q1Published status: Under Pressure
Revenue reaches at least $175 million by mid-2028Revenue: $0

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-45.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

SAB Biotherapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is in a watch state: management is advancing studies and manufacturing plans, but recent financial performance is weak and the risk label is high.

What's priced into SAB Biotherapeutics Inc

The valuation model shows a premium versus peers, while its expectations gap is elevated and the market setup is tagged as unjustified. In plain terms, expectations appear difficult to support given ongoing losses, no current revenue, and clinical uncertainty; confidence in this assessment is medium.

What the fundamentals likely do

Near term, operating losses are likely to continue as the company funds clinical development, with no revenue impact yet from its manufacturing partnership. Enrollment completion for the Phase 2b SAFEGUARD study is expected by Q4 2026, with topline data anticipated in the second half of 2027. Near-term execution risk is elevated, including a stated risk of another earnings miss, and litigation filings are a recent negative development.

What SAB Biotherapeutics Inc hinges on

The multi-year thesis hinges on completing the SAB-142 studies and producing useful clinical results, alongside making progress toward manufacturing readiness. A guidance cut or further weakening in employment could add pressure to the business outlook, while stronger results and guidance from healthcare sector bellwethers could support sector momentum. The evidence does not establish how these factors will resolve.